Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 3/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.43 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.43 |
| ▸ | GSK3A | P49840 | 2/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | IKBKB | O14920 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2303678 | 0.76 | PIM1 (0.44) | HPGDKDM4EALDH1A1KMT2APOLB | |
| SCHEMBL2303335 | 0.75 | CYP1A2 (0.32) | HPGDALDH1A1CYP1A2TMIGD3CYP2C9 | |
| SCHEMBL278692 | 0.75 | CDC7 (0.51) | HPGDKDM4EALDH1A1KMT2APOLB | |
| SCHEMBL2303771 | 0.74 | KDM4A (0.47) | HPGDKDM4EALDH1A1KMT2APOLB | |
| SCHEMBL2302798 | 0.71 | KDM4A (0.51) | HPGDKDM4EALDH1A1KMT2APOLB | |
| SCHEMBL2300781 | 0.70 | PIM1 (0.47) | HPGDKDM4EALDH1A1KMT2APOLB | |
| SCHEMBL21048228 | 0.69 | CLK1 (0.64) | HPGDKDM4EALDH1A1HSD17B10PIM1 | |
| SCHEMBL6111581 | 0.69 | KDM4E (0.41) | HPGDKDM4EALDH1A1KMT2AMAPK1 | |
| SCHEMBL4208864 | 0.68 | KRAS (0.51) | KDM4ESMN1; SMN2PIM1PIM3CLK4 | |
| SCHEMBL8277908 | 0.67 | KDM4E (0.49) | HPGDKDM4EALDH1A1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989464-B2 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2011-08-02 | — | — | US | disclosed |
| EP-1765829-B1 | TRICYCLIC COMPOUNDS AND THEIR USE AS MGLUR1 ANTAGONISTS | SCHERING CORP (US) | 2010-07-07 | — | — | EP | disclosed |
| US-7598259-B2 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090192178-A1 | mGluR1 ANTAGONISTS AS THERAPEUTIC AGENTS | SCHERING CORPORATION | 2009-07-30 | — | — | US | disclosed |
| US-20090082336-A1 | mGluR1 Antagonists as Therapeutic Agents | SCHERING CORPORATION | 2009-03-26 | — | — | US | disclosed |
| US-7485648-B2 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2009-02-03 | — | — | US | disclosed |
| WO-2006010568-A3 | SUBSTITUTED PYRIDO[3',2':4,5]THIENO[3,2-D]PYRIMIDINE-2,4(1 H,3H)-DIONES AND -4(3H)-ONES, PYRIDO[3',2':4,5]FURO[3,2-D]PYRIMIDINE-2,4(1 H,3H)-DIONES AND -4(3H)-ONES, AND USE THEREOF AS INHIBITORS OF TNF-ALPHA RELEASE | CURACYTE DISCOVERY GMBH (DE) | 2006-09-14 | — | — | WO | disclosed |
| US-20060167029-A1 | mGluR1 Antagonists as therapeutic agents | SCHERING CORPORATION | 2006-07-27 | — | — | US | disclosed |
| WO-2006010568-A2 | SUBSTITUTED PYRIDO[3',2':4,5]THIENO[3,2-D]PYRIMIDINE-2,4(1 H,3H)-DIONES AND -4(3H)-ONES, PYRIDO[3',2':4,5]FURO[3,2-D]PYRIMIDINE-2,4(1 H,3H)-DIONES AND -4(3H)-ONES, AND USE THEREOF AS INHIBITORS OF TNF-ALPHA RELEASE | CURACYTE DISCOVERY GMBH (DE) | 2006-02-02 | — | — | WO | disclosed |
| US-20060009477-A1 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION | 2006-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192178-A1 | mGluR1 ANTAGONISTS AS THERAPEUTIC AGENTS | GRM1, GRM4, GRIA1 | HPGD 1200/4885KDM4E 1129/4885ALDH1A1 1026/4885 |
| US-20060167029-A1 | mGluR1 Antagonists as therapeutic agents | GRM1, GRM4, GRIA1 | HPGD 1200/4885KDM4E 1129/4885ALDH1A1 1026/4885 |
| US-20060009477-A1 | mGluR1 antagonists as therapeutic agents | GRM1, GRM4, GRIA1 | HPGD 1207/4885KDM4E 1129/4885ALDH1A1 966/4885 |
| US-20090082336-A1 | mGluR1 Antagonists as Therapeutic Agents | GRM1, GRM4, GRIA1 | HPGD 1200/4885KDM4E 1129/4885ALDH1A1 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.